A case report: Does aminophylline have opportunity in covid-19 management?

Research output: Contribution to journalArticlepeer-review


The novel coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2), which causes severe acute respiratory distress syndrome (ARDS). ARDS causes the patient to have difficulty breathing, the appearance of pneumonia from chest radiological images, and from the examination results by pulse oximetry, the picture of oxygenation is poor. Most clinical complaints require mechanical ventilation and treatment in the intensive care unit (ICU). We made several attempts to increase oxygenation and ventilation from a pharmacological and non-pharmacological perspective. From pharmacology, given drugs that help from an immunological aspect, reduce preload, help cardiac contractility, and anti-virus. In this case report, we report aminophylline administration as a therapeutic modality in critically ill patients' handling due to COVID-19.

Original languageEnglish
Pages (from-to)46-51
Number of pages6
JournalCritical Care and Shock
Issue number1
Publication statusPublished - 2021


  • COVID-19
  • Immunomodulator
  • Intravenous aminophylline


Dive into the research topics of 'A case report: Does aminophylline have opportunity in covid-19 management?'. Together they form a unique fingerprint.

Cite this